Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") announces that it has received $209,764.05 in cash proceeds from the exercise of previously issued warrants, finder's warrants and stock options. The proceeds will be allocated to continue to move the Company forward towards cash flow.
Brent Willis, CEO of Voyageur, states “We are very appreciative to all the shareholders who continue to support our Company. We would like to thank those shareholders who are exercising their warrants prior to their pending expiry dates. We will continue to stay focused on cash flow and development of our Flag Ship property, Frances Creek”.
About Voyageur
Voyageur Pharmaceuticals Ltd. is a Canadian public company listed on the TSX Venture Exchange under the trading symbol VM. Voyageur is focused on the development of drugs related to the minerals barite and iodine as Active Pharmaceutical Ingredients ("API") minerals. The near-term focus is developing barium and iodine radiographic contrast products. Voyageur’s goal is to initially generate positive cash flow from operations using third party pharmaceutical manufacturers. Ultimately, Voyageur will be building the required infrastructure to become 100% self-sufficient with all manufacturing of drugs and API minerals. Voyageur owns a 100% interest in three barium sulfate (barite) projects including its 100% owned Frances Creek barium sulfate property and also owns interests in an iodine, lithium and bromine heavy mineral brine project located in Utah, USA. Voyageur is moving forward with its business plan of becoming the only fully-integrated company in the radiographic contrast medical field by controlling all primary input costs under the slogan of: "From the Earth to the Bottle".
For further information, please contact:
Ron Love, CFO, Cell: (403) 818-6086, This email address is being protected from spambots. You need JavaScript enabled to view it.
Brent Willis, CEO, This email address is being protected from spambots. You need JavaScript enabled to view it.
www.voyageurpharmaceuticals.ca
Reader Advisory
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.
Forward Looking Information
This news release may contain certain forward-looking information and statements, including without limitation, statements pertaining to the entering into of a definitive manufacturing contract with AVL. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company's disclosure documents on the SEDAR website at www.sedar.com. Voyageur does not undertake to update any forward-looking information except in accordance with applicable securities laws.
